A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 as Well as the Impact of AZD4144 on the Pharmacokinetics of Rosuvastatin and Furosemide in Healthy Participants
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
91actual
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-07-15 | actual | When the study began enrolling |
| Primary completion | 2025-06-11 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-06-11 | actual | The whole study's end, after follow-up |
| First posted | 2024-07-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-07-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Participants
Interventions
- Drug: AZD4144- Part A
- Drug: Placebo- Part A
- Drug: AZD4144- Part B
- Drug: Placebo- Part B
- Drug: Rosuvastatin and Furosemide- Part C
- Drug: Rosuvastatin, Furosemide, and AZD4144 Part C
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with adverse events (AEs) (Part A and Part B)
measured Part A: Day 1 to Day 10+3; Part B: Day 1 to Day 20+3.
Area under plasma concentration-time curve from time 0 to infinity (AUCinf) (Part C)
measured Treatment period 1: Day 1 to 3; Treatment period 2: Day 10 to 12.
Area under concentration-curve from time 0 to the last quantifiable concentration (AUClast) (Part C)
measured Treatment period 1: Day 1 to 3; Treatment period 2: Day 10 to 12.
Maximum observed drug concentration (Cmax) (Part C)
measured Treatment period 1: Day 1 to 3; Treatment period 2: Day 10 to 12.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed